Accurate and time-saving, two-step intracavernosal injection procedure to diagnose psychological erectile dysfunction

Daniele Santi, Giorgia Spaggiari, Manuela Simoni, Antonio R. M. Granata

Unit of Endocrinology, Department of Medical Specialties, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy

Abstract

**Background:** The recognition of the erectile dysfunction pathogenesis is essential to identify the appropriate erectile dysfunction management. As vascular erectile dysfunction could be a manifestation of a systemic arterial damage, the watershed in the erectile dysfunction diagnostic framework is the discrimination between psychological erectile dysfunction and vascular erectile dysfunction. However, reliable tools to directly diagnose psychological erectile dysfunction are currently lacking.

**Objective:** To identify which parameters could predict psychological erectile dysfunction. Moreover, we suggest a new intracavernosal injection procedure to optimize the erectile dysfunction diagnostic workup.

**Materials and methods:** A retrospective, real-world analysis was carried out including all men who underwent intracavernosal injection procedure at the Modena Andrology Unit from 2018 to 2021. A first intracavernosal injection procedure with 5 µg of prostaglandin E-1 (PGE-1) was performed. In the absence of a full drug-induced erection (immediate or delayed), an echo-color Doppler penile evaluation after administration of PGE-1 10 µg was conducted, measuring intracavernosal blood flows, to document a possible vascular etiology. Hormonal evaluations were performed.

**Results:** Out of 179 enrolled patients, 70.4% showed psychological erectile dysfunction, 21.7% vascular erectile dysfunction, and 7.8% hormonal genesis. Multinomial logistic regression analysis identified absence of cardiovascular disease ($p = 0.017$), presence of spontaneous morning erections ($p = 0.018$), and normal penile erections with masturbation ($p = 0.035$) as predictors of psychological erectile dysfunction. Clinically, normal intracavernosal injection test response was detected in 86 patients and abnormal response in 93 subjects. Among the latter, 54 patients experienced a delayed response. The combination of intracavernosal injection test with late penile erections evaluation was able to diagnose psychological erectile dysfunction (sensitivity 97%, specificity 100%), avoiding unnecessary retesting.

**Discussion:** We propose a two-step intracavernosal injection procedure that allows to recognize psychological erectile dysfunction with a high sensitivity/specificity, saving costs and time, and limiting adverse events. Moreover, the presence of spontaneous morning erections could be a valid marker of psychological erectile dysfunction.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2022 American Society of Andrology and European Academy of Andrology.
1 | INTRODUCTION

Erectile dysfunction (ED) is defined as the inability to achieve and/or maintain a penile erection sufficient to obtain satisfactory sexual activity. Worldwide, the ED prevalence is very high, affecting up to 25% of men in the general population and 70% in elderly. Not surprisingly, ED represents the first reason that leads the males to seek an andrological consultation.

Many scientific societies developed different guidelines and position statements on the ED management. All these recommendations highlight the relevance to achieve an accurate diagnosis of the ED etiology, applying a comprehensive evaluation and targeted physical examination. In this setting, many validated questionnaires for ED evaluation could be applied, with the aim to quantify a subjective symptom (i.e., ED) and, overall, to initiate a conversation with the patient about ED. Indeed, the andrologist works in a delicate context, unravelling intimate and private information, in which psychological implication must be considered in order to avoid obtaining only a superficial evaluation of the disorder. In this setting, the main goal of the andrologist is the identification of the ED etiology, distinguishing among psychological, neurologic, hormonal, and vascular forms. In this setting, the most frequent form is expected to be of psychogenic origin. On the other hand, 50%–80% of all cases of organic ED are because of arterial insufficiency of the penile vessels and must be recognized, as the presence of ED could be considered a hallmark of future minor and major cardiovascular events. Vascular ED and major cardiovascular events could be considered different manifestations of the same systemic arterial damage that, because of the small diameter of penile arteries, causes sexual dysfunction earlier than other events. While a normal erectile function consists of an adequate arterial inflow and a poor or absent venous outflow, in the presence of impaired cavernosal smooth muscle relaxation or arterial inflow stenosis erection is impaired. The temporal connection between ED vascular forms and major cardiovascular events justifies the need to reach an accurate diagnosis for each man claiming for sexual dysfunction, in order to initiate appropriate diagnostic-therapeutic and preventive procedures.

Specialized tests are required to examine the vascular component of erection, such as intracavernosal injection (ICI) and penile Doppler ultrasound. These tools are dynamic tests, performed by an experienced sonographer in a physician’s office or in a hospital setting, providing the injection of vasoactive drugs to examine penile blood flows. Although these examinations are objective and reliable, they are used only to rule out a vasculogenic cause, not permitting a comprehensive ED evaluation. Moreover, they are invasive and require skilled personnel, modern equipment, relatively high costs and time, limiting the use of these examinations in many clinical settings. In addition, potential adverse events should be considered, such as priapism, penile pain, and/or general discomfort. Although priapism occurs only in 2%–3% of examinations, its management is very complex and challenging. For this reason, several vasoactive drugs have been tested, such as papaverine, prostaglandin E (PGE)-1, phentolamine, or their combination (TRIMIX - papaverine 4.4 mg, phentolamine 0.15 mg, and PGE-1 1.5 µg in 0.25 ml of physiological solution) to reduce the adverse event risk. PGE-1 is still the vasoactive drug mostly used in ICI examination, and the priapism risk in this context is directly related to the dosages used. Thus, the lowest possible PGE-1 dosage is generally suggested to perform ICI examination. However, using safe PGE-1 doses results in reduced test accuracy, with an increased risk of having to repeat the procedure, thereby increasing costs and potential adverse effects.

Considering the difficulty to reach or rule out a vascular component of ED, together with the high incidence of psychogenic forms, a first discrimination between psychological and organic ED is fundamental to tailor the clinical management. Whether some cases are clearly because of psychological causes (i.e., stressful events, selective ED, etc.), an accurate tool to measure the psychological distress in sexual dysfunction is still lacking. Thus, we designed this retrospective analysis of real-world data to detect which parameters routinely collected during andrological examination could predict psychogenic ED, focusing on a reliable ICI procedure to increase its accuracy to rule out psychological causes, reducing adverse events and time and cost.

2 | MATERIALS AND METHODS

2.1 | Study design

This is a retrospective clinical trial based on real-world data. The study protocol was approved by the Ethics Committee of “Area Vasta Emilia Nord” (protocol number: AOU0024637/19 of 12/09/2019).

All men consecutively evaluated with ICI procedure at the Andrology Unit of the University of Modena and Reggio Emilia from January 2018 to December 2021 were enrolled. The ICI procedure was proposed to all patients in which history collection did not allow to define a...
2.2 | Data collection

The routine protocol consisted of medical history collection by unstructured interview, including age, smoking status, alcohol intake, number and type of comorbidities, number and type of drugs chronically assumed, and history of cardiovascular disease (Figure 1).

ED was thoroughly investigated considering its onset period, duration, severity, possible situational factors, presence/absence of morning erections, presence/absence of masturbatory ED, and prior use of pro-erectogenic therapies (Figure 1). ED severity was quantified using both the International Index of Erectile Function (IIEF)-5 and the ED domain at IIEF-15.27

Considering medical history, an ICI procedure with vasoactive agents was proposed to exclude a vascular ED component. The ICI test was performed following a two-stage procedure. In the first step, the lowest PGE-1 dosage possible (5 µg) was used.28 This step was performed by MD residents as described previously.29 In brief, 8–10 min after the injection, the drug-induced erection was assessed using a buckling device (Rigid test, Androline srl, Milan, Italy). A full erection was recorded in case of absent penile buckling when a 1000 g...
downward force was slowly applied to the glans, following the erect shaft axis. To assess the gradual nature of the response, patients were divided into four groups according to the buckling test graduation: (I) absent <500 g, (II) mild 500–750 g, (III) moderate 750–1000 g, and (IV) optimal response >1000 g. From a clinical point of view, a normal response was considered when the buckling examination was higher than 750 g.

The second step of the procedure consisted of the echo-color Doppler penile evaluation (ECD) after PGE-1 10 µg injection. This second procedure was performed on a separate day by the same skilled and experienced andrologist for all patients. Before proceeding to the PGE-1 injection, the patient was asked whether the penile erection obtained during the first procedure (ICI test) increased when he left the hospital. The ECD test was then performed when the buckling response to ICI test was lower than 750 g and the patient did not experience any change at home. During ECD, the penile response was evaluated with both buckling test and ultrasound evaluation, measuring the systolic peak and end-diastolic peak velocities at the right and left cavernous arteries of the penis. The systolic peak velocity provides an indirect information about the arterial filling of the corpora cavernosa, while the end-diastolic velocity, about its emptying. Normal responses were considered when systolic peak was higher than 30 mm/s and end-diastolic lower than 5 mm/s. During each step of the ICI procedure, safety was evaluated, reporting cases of priapism and penile pain occurring during and/or after injection.

Hormonal assessment was performed before the ICI procedure, consisting of testosterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol, prostate-specific antigen (PSA), prolactin, and thyroid-stimulating hormone (TSH) serum levels, to highlight a possible hormonal cause of the ED.

### 2.3 Classification procedures

Vascular ED was defined when a complete erection was not obtained after the entire ICI procedure, with systolic velocity at ECD lower than reference ranges and/or end-diastolic velocity higher than thresholds suggested. Hormonal ED was defined when reduced testosterone serum levels (below 3 ng/ml) were detected, irrespective of the ICI procedure response. A psychological ED form was diagnosed when normal results were obtained from both ICI procedure and hormonal evaluation.

### 2.4 Statistical analysis

Data distribution was evaluated by Kolmogorov–Smirnov test. Comparisons of continuous variables among groups were performed by ANOVA univariate and/or Kruskal–Wallis test, according to data distribution. Tukey key test was performed for post hoc analyses. Mann–Whitney U-test was used when two groups of continuous variables were present. Categorical parameters were compared among groups using Fisher exact test.

The analysis was first performed dividing the cohort of patients into three groups, according to ED etiology, that is, psychological, vascular, and hormonal. Then, the analysis was repeated considering the normal/abnormal response to the first step of ICI procedure. Finally, the analysis was repeated considering the normal/abnormal response to the overall ICI procedure.

In order to predict both psychological ED and normal ICI response, multinomial logistic regression analyses were performed at each step of data analysis. Results from logistic regressions were reported as odds ratio (OR) along with their 95% confidence interval (CI).

All statistical analyses were performed using the “Statistical Package for the Social Science” software for Windows (version 27.0; SPSS Inc., Chicago, IL). Statistical significance was considered for p < 0.05.

### 3 RESULTS

One hundred seventy-nine patients were enrolled. Table 1 summarizes patients’ characteristics. As expected, 70.4% (126 patients) showed a psychological ED. Thus, organic ED was detected in 53 subjects (29.6%), divided in vascular (39 patients, 21.7% of the entire cohort) and hormonal (14 men, 7.8%) forms. Patients with vascular ED showed higher age compared to other groups (Table 1), whereas no differences were detected for body mass index (BMI).

Considering the answers to a validated questionnaire, scores of both IIEF-5 and the ED domain at IIEF-15 were significantly different among groups (p < 0.001). At post hoc analysis, lower scores were detected in vascular compared to psychological ED, whereas no differences were detected with hormonal forms (Table 1). Moreover, psychological ED showed lower rate of severe ED and higher rate of mild forms compared to organic groups (Table 1).

Considering the information collected during the unstructured interview, psychological ED was characterized by higher incidence of spontaneous morning erections and normal penile erection with masturbation, compared to organic forms (Table 1). Sexual desire was evaluated both by direct questioning by the clinician during the anamnestic interview and by IIEF-15-related domain (questions 11 and 12). These two methods significantly correlated together (Spearman rho 0.188, p = 0.013), suggesting the potential overlap of unstructured and structured interviews. However, sexual desire impairment showed a similar incidence among groups (Table 1).

Cardiovascular diseases were less frequent in psychological ED compared to organic forms, as expected (Table 1). On the contrary, dyslipidemia was more frequent in hormonal compared to both psychological and vascular ED (Table 1). Hypertension and diabetes mellitus rates did not differ among groups (Table 1). Considered all comorbidities together, the comorbidity number and the drug number of drug chronically used did not differ among groups (Table 1).

In order to predict psychological ED, multinomial logistic regression analysis was performed, revealing three relevant variables (Table 2). In details, psychological ED was predicted by the absence of cardiovascular disease (p = 0.017), the presence of normal penile erection with masturbation (p = 0.035), and the presence of spontaneous morning erection (p = 0.035).
highlight the pathogenesis, apart from hormonal forms. However, interestingly hormones did not help the clinician to differentiate are expected, as hormonal ED diagnosis is based on hormonal levels. However, interestingly hormones did not help the clinician to highlight the pathogenesis, apart from hormonal forms.

### TABLE 1  Characteristics of the patients who are compared according to the erectile dysfunction etiology

|                  | Overall (n = 179) | Psychological (n = 126) | Vascular (n = 39) | Hormonal (n = 14) | p-Value |
|------------------|------------------|------------------------|------------------|------------------|---------|
| Age (years)      | 55.7 ± 11.0      | 54.0 ± 11.3            | 60.7 ± 9.2<sup>a</sup> | 57.2 ± 9.4       | 0.004   |
| Body mass index (kg/m<sup>2</sup>) | 29.2 ± 5.2 | 28.6 ± 4.8           | 29.7 ± 5.9        | 32.4 ± 5.6       | 0.138   |
| Current smoker, n (%) | 49 (27.2) | 39 (31.0)            | 6 (15.4)           | 4 (28.6)         | 0.162   |
| Ex-hypertension, n (%) | 61 (33.9) | 40 (31.7)            | 17 (43.6)          | 4 (28.6)         | 0.356   |
| Hypertension, n (%) | 79 (43.4) | 53 (42.1)            | 20 (51.3)          | 6 (42.9)         | 0.596   |
| Diabetes mellitus, n (%) | 58 (32.2) | 36 (28.6)            | 16 (41.0)          | 6 (42.9)         | 0.238   |
| Dyslipidemia, n (%) | 55 (30.6) | 31 (24.6)            | 14 (35.9)<sup>a</sup> | 10 (71.4)<sup>a</sup> | 0.001   |
| Cardiovascular diseases, n (%) | 28 (15.6) | 14 (11.1)            | 9 (23.1)<sup>a</sup> | 5 (35.7)<sup>a</sup> | 0.020   |
| Comorbidities number | 1.59 ± 1.3 | 1.5 ± 1.3            | 1.8 ± 1.3          | 1.8 ± 1.3        | 0.258   |
| Chronic treated patients, n (%) | 131 (72.8) | 91 (72.2)            | 29 (74.4)          | 11 (78.6)        | 0.863   |
| Drugs number     | 2.6 ± 3.0       | 2.4 ± 2.7             | 3.4 ± 3.8          | 2.9 ± 2.9        | 0.140   |
| IIEF-5 score     | 10.6 ± 6.1      | 11.6 ± 6.1            | 7.3 ± 4.9<sup>a</sup> | 10.2 ± 6.2       | 0.001   |
| Erectile dysfunction at IIEF-15, n (%) | 10.7 ± 8.1 | 11.8 ± 8.3          | 7.7 ± 6.6<sup>a</sup> | 9.3 ± 8.0        | 0.015   |
| Erectile dysfunction at IIEF-15, n (%) |       |                     |                   | 0.007            |
| Severe           | 101 (56.1)      | 61 (50.0)             | 29 (76.3)<sup>a</sup> | 11 (78.6)<sup>a</sup> | -       |
| Moderate         | 26 (14.4)       | 21 (17.2)             | 4 (10.5)           | 1 (7.1)          | -       |
| Mild             | 39 (21.7)       | 34 (27.9)             | 4 (10.5)<sup>a</sup> | 1 (7.1)<sup>a</sup> | -       |
| Absent           | 8 (4.4)         | 6 (4.9)               | 1 (2.6)            | 1 (7.1)          | -       |
| ED duration (months) | 41.7 ± 40.5 | 39.3 ± 41.0          | 47.8 ± 37.7        | 46.8 ± 45.3      | 0.484   |
| ED duration > 2 years, n (%) | 84 (46.9) | 53 (42.1)            | 23 (59.0)          | 8 (57.1)         | 0.132   |
| ED during masturbation, n (%) | 66 (36.7) | 29 (24.0)            | 30 (78.9)          | 7 (50.0)         | <0.001  |
| Impaired morning erections n (%) | 58 (32.2) | 26 (20.6)            | 25 (64.1)          | 7 (50.0)         | <0.001  |
| Decreased sexual desire, n (%) | 46 (25.6) | 34 (27.0)            | 7 (17.9)           | 5 (35.7)         | 0.355   |
| Total testosterone (ng/ml) | 4.8 ± 1.7 | 5.0 ± 1.4            | 5.0 ± 2.0<sup>a</sup> | 2.2 ± 0.3<sup>a</sup> | <0.001  |
| LH (IU/L) | 4.4 ± 2.1 | 4.3 ± 2.2           | 4.8 ± 2.2          | 3.9 ± 1.0        | 0.352   |
| FSH (IU/L) | 6.2 ± 5.5 | 6.1 ± 5.3            | 6.9 ± 6.9          | 5.5 ± 2.1        | 0.717   |
| Estradiol (pg/ml) | 24.2 ± 9.0 | 24.0 ± 8.9          | 27.5 ± 9.4<sup>a</sup> | 18.7 ± 5.5<sup>a</sup> | 0.009   |
| Prostate-specific antigen (ng/ml) | 1.3 ± 1.2 | 1.3 ± 1.2           | 1.4 ± 1.5          | 1.1 ± 0.8        | 0.752   |
| Prolactin (ng/ml) | 11.1 ± 5.1 | 11.0 ± 5.1          | 12.2 ± 5.4         | 8.8 ± 4.0        | 0.143   |
| TSH (mU/ml) | 2.1 ± 3.9 | 2.3 ± 4.7           | 1.6 ± 0.9          | 2.0 ± 1.0        | 0.657   |

Note: Continuous variables are reported as mean ± standard deviation, categorical variables are reported as number (percentage). p-Values are obtained by Kruskal–Wallis test.

Abbreviations: ED, erectile dysfunction; FSH, follicle-stimulating hormone; IIEF, International Index on Erectile Function; LH, luteinizing hormone; TSH, thyroid-stimulating hormone.

<sup>a</sup>Significantly different from psychological forms at post hoc analyses (Tukey test).

<sup>b</sup>Significantly different from hormonal forms at post hoc analyses (Tukey test).

3.1 ICI procedure

No major procedure-related adverse events, especially priapism and penile pain, were recorded in both ICI and ECD steps of our procedure.

Considering the first step of the procedure (ICI test), insufficient results (<500 g at buckling examination) were obtained in 62 patients (34.4%) and optimal responses (>1000 g) in 69 patients (38.3%). Intermediate results were obtained in 31 (17.2%) and 17 (9.4%) patients, considering 500–750 g and 750–1000 g, respectively. Thus, clinically...
normal ICI test response (>750 g) was detected in 86 patients and abnormal (<750 g) in 93 subjects.

As expected, patients with normal ICI test were younger and showed higher score at both IIEF-5 and IIEF-15 (Table 3). Severe ED was more frequent in men with impaired compared to normal ICI test (p < 0.001). Moreover, patients with normal ICI test showed a lower incidence of both ED with masturbation and impaired spontaneous morning erection, compared to those with altered ICI test (Table 3). Although the number of comorbidities and drugs did not differ between groups, patients with impaired ICI test were more frequently chronically treated, compared to patients with normal response (p = 0.033) (Table 3). Finally, hormones did not differ between groups (Table 3), confirming their limited predictive role.

Multinomial logistic regression analysis showed that only the absence of spontaneous morning erection significantly predicted the ICI test results (Table 4).

Considering the second step of our procedure (ECD), 54 patients (49.1%) with abnormal buckling result during ICI test experienced a complete penile erection after leaving the hospital. Thus, an overall number of 123 patients (68.7% of the entire cohort) obtained a complete response to ICI test. This late ICI response was not predicted by any parameter collected (Table 5), suggesting the relevance to evaluate this unpredictable variable. Thus, only three patients (2.4%) with psychological ED did not respond to the entire ICI procedure and required the ECD examination. The combination of ICI test with the evaluation of the late penile erection was able to diagnose psychological ED with high accuracy (sensitivity: 97%, specificity: 100%). In this way, 54 patients not responding to the first step of the procedure were spared from undergoing a new PGE-1 injection with higher dosage.

Patients with a normal result throughout the overall ICI procedure were younger, with higher IIEF-5 and IIEF-15 scores (Table 5). Accordingly, a higher incidence of severe ED was detected in patients with abnormal overall response (Table 5). Moreover, a normal result to ICI procedure was associated to lower rate of both ED at masturbation and impaired spontaneous morning erections (Table 5).

Finally, ECD was performed in 42 patients, with a mean systolic peak velocity of 25.3 ± 10.1 and 24.3 ± 12.4 cm/s (right and left sides, respectively) and an end-diastolic peak of 5.1 ± 2.3 and 4.5 ± 2 cm/s. As expected, ECD parameters were significantly higher in patients with psychological compared to organic ED (Table 6).

| TABLE 2 | Multinomial logistic regression analysis performed to predict psychological erectile dysfunction |
|---------|--------------------------------------------------|
| Intercept | 0.194 | 1.822 | 0.011 | 0.915 |
| Comorbidities number | −0.218 | 0.326 | 0.448 | 0.503 | 0.804 | 0.424 | 1.524 |
| Drug number | −0.016 | 0.108 | 0.022 | 0.882 | 0.984 | 0.797 | 1.215 |
| ED duration | 0.002 | 0.006 | 0.096 | 0.757 | 1.002 | 0.990 | 1.014 |
| IIEF-5 | −0.097 | 0.068 | 2.031 | 0.154 | 0.908 | 0.794 | 1.037 |
| ED at IIEF-15 | 0.030 | 0.050 | 0.364 | 0.546 | 1.030 | 0.935 | 1.136 |
| Smoke | 0.686 | 0.585 | 1.372 | 0.241 | 1.985 | 0.630 | 6.255 |
| Ex-smoke | 0.137 | 0.516 | 0.071 | 0.790 | 1.147 | 0.417 | 3.152 |
| Alcohol | 0.350 | 0.493 | 0.502 | 0.479 | 1.419 | 0.539 | 3.732 |
| No hypertension | −0.194 | 0.599 | 0.105 | 0.746 | 0.824 | 0.255 | 2.663 |
| No diabetes mellitus | −0.059 | 0.578 | 0.010 | 0.918 | 0.942 | 0.304 | 2.926 |
| No dyslipidemia | −0.904 | 0.625 | 2.095 | 0.148 | 0.405 | 0.119 | 1.377 |
| No cardiovascular diseases | −1.557 | 0.654 | 5.676 | 0.017 | 0.211 | 0.059 | 0.759 |
| Impaired sexual desire | −0.224 | 0.520 | 0.185 | 0.667 | 0.800 | 0.289 | 2.213 |
| ED with masturbation | 1.068 | 0.508 | 4.421 | 0.035 | 2.909 | 1.075 | 7.871 |
| No morning erection | 1.278 | 0.539 | 5.617 | 0.018 | 3.589 | 1.248 | 10.327 |
| Gradual onset of ED | 0.796 | 0.656 | 1.473 | 0.225 | 2.217 | 0.613 | 8.023 |
| Constant ED | −0.714 | 0.544 | 1.722 | 0.189 | 0.489 | 0.168 | 1.423 |

Abbreviations: CI, confidence interval; ED, erectile dysfunction; IIEF, International Index on Erectile Function; OR, odds ratio; SE, standard error.
TABLE 3  Characteristics of the patients who are compared according to normal or abnormal penile response to ICI

|                      | ICI normal response (n = 86) | ICI reduced response (n = 93) | p-Value |
|----------------------|-----------------------------|-------------------------------|---------|
| Age (years)          | 53.2 ± 11.6                 | 58.1 ± 10.0                   | 0.003   |
| Body mass index (kg/m²) | 28.8 ± 4.6                 | 29.6 ± 5.6                    | 0.448   |
| Current smoker, n (%) | 29 (33.7)                   | 20 (21.5)                     | 0.067   |
| Ex-smoker, n (%)     | 24 (27.9)                   | 37 (39.8)                     | 0.094   |
| Hypertension, n (%)  | 32 (37.2)                   | 47 (50.5)                     | 0.073   |
| Diabetes mellitus, n (%) | 23 (26.7)               | 35 (37.6)                     | 0.120   |
| Dyslipidemia, n (%)  | 22 (25.6)                   | 33 (35.5)                     | 0.151   |
| Cardiovascular diseases, n (%) | 10 (11.6)        | 18 (19.4)                     | 0.155   |
| Comorbidities number | 1.5 ± 1.3                   | 1.7 ± 1.2                     | 0.224   |
| Chronic treated patients, n (%) | 57 (66.3)           | 74 (79.6)                     | 0.033   |
| Drugs number         | 2.3 ± 3.0                   | 2.9 ± 3.0                     | 0.261   |
| IIEF-5 score         | 12.3 ± 6.2                  | 9.0 ± 5.6                     | <0.001  |
| Erectile domain at IIEF-15 | 12.7 ± 8.8              | 8.9 ± 7.0                     | 0.002   |
| Erectile dysfunction at IIEF-15, n (%) | 65 (71.4)            | 9.0 ± 5.6                     | <0.001  |
| Severe               | 36 (43.4)                   | 65 (71.4)                     | –       |
| Moderate             | 17 (20.5)                   | 9 (9.9)                       | –       |
| Mild                 | 25 (30.1)                   | 14 (15.4)                     | –       |
| Absent               | 5 (6.0)                     | 3 (3.3)                       | –       |
| ED duration (months) | 37.7 ± 34.9                 | 45.3 ± 44.8                   | 0.213   |
| ED duration > 2 years, n (%) | 41 (47.7)               | 43 (46.2)                     | 0.847   |
| ED during masturbation, n (%) | 46 (51.1)             | 61 (73.5)                     | 0.002   |
| Impaired morning erections, n (%) | 52 (55.9)           | 69 (80.2)                     | <0.001  |
| Decreased sexual desire, n (%) | 21 (24.4)            | 25 (26.9)                     | 0.706   |
| Total testosterone (ng/ml) | 4.7 ± 1.6               | 4.8 ± 1.8                     | 0.680   |
| LH (IU/L)            | 4.4 ± 2.1                   | 4.4 ± 2.1                     | 0.988   |
| FSH (IU/L)           | 5.9 ± 4.4                   | 6.5 ± 6.5                     | 0.535   |
| Estradiol (pg/ml)    | 23.5 ± 8.0                  | 24.8 ± 9.8                    | 0.368   |
| Prostate-specific antigen (ng/ml) | 1.3 ± 1.2              | 1.3 ± 1.3                     | 0.743   |
| Prolactin (ng/ml)    | 11.1 ± 5.3                  | 11.0 ± 5.0                    | 0.858   |
| TSH (µIU/ml)         | 1.9 ± 1.0                   | 2.4 ± 5.4                     | 0.504   |

Note: Continuous variables are reported as mean ± standard deviation, categorical variables are reported as number (percentage). p-Values are obtained by Mann–Whitney U-test.
Abbreviations: ED, erectile dysfunction; FSH, follicle-stimulating hormone; ICI, intracavernosal injection; IIEF, International Index on Erectile Function; LH, luteinizing hormone; TSH, thyroid-stimulating hormone.

The ICI test remains the gold standard approach to diagnose vascular ED. Although ICI accuracy to rule out a vascular etiology is high, it is not able to completely overtake the psychological component of the penile erection, as the patient could experience a variable degree of discomfort during the diagnostic procedure. Because psychological factors could affect the reliability of ICI test, the so-called retesting approach has been suggested for overcoming the psychological effect in selected patients.31,32 Thus, although not reported in current clinical guidelines, the andrologist should consider performing ICI test twice if the normal penile response is not achieved at the first time. Previously, several authors suggested that manual and visual sexual stimulation was applied after vasoactive agent injection to increase the rigidity of erection and if the patient still did not achieve the erection quality at home, a re-dosing should be considered.33,34 This strategy, aimed at avoiding a second step of vasoactive agent injection is currently applied in clinical practice but it cannot overcome possible psychological issues. Thus, we used a two-step ICI procedure, in which two consecutive diagnostic phases are provided, increasing PGE-1 dosage and evaluating the potential late onset of complete penile erection once the patient exits the hospital. Although this approach requires a two-step...
When predictive logistic models were applied in this study, the anamnestic evaluation remained the strong factor to suspect psychological ED. In particular, ED characteristics with a specific focus on the symptom characteristics in settings other than sexual intercourses, and the presence of spontaneous morning erections could guide the diagnostic ED workup. Even if several questionnaires have been validated so far to grade ED, they are not useful to discriminate among ED etiologies. Although psychological ED showed a lower IIEF-5 and IIEF-15 score compared to both vascular and hormonal forms, these variables did not enter in the predictive model. The main difference between structured and unstructured interviews lies in the possibility for the patient to self-fill in case of validated questionnaires without the need for clinician intervention. This aspect certainly represents an advantage in the andrological field, where the issues addressed are intimate and personal and the patient may experience some degree of embarrassment. For these reasons, obtaining ED characteristics by unstructured interviews requires a fully functioning trustworthy relationship between the clinician and the patient, because this relationship is known to guide decision-making and to influence the therapeutic success in many clinical settings. Here, we highlight how a strong clinician–patient relationship provides fundamental information that could help the clinician to unravel the ED diagnostic challenge. This aspect appears even more relevant when considering anthropometrical variables. Although psychological ED is more frequent in younger subjects, the age of the patients did not predict the ED etiology in any of the logistic regressions performed. Similarly, BMI did not enter in predictive models.

Access of the patient to the outpatient clinic, it allows a more reliable, accurate, safe, and cheap diagnostic detection of psychological forms. With this procedure, we are able to quantify the high expected prevalence of psychological ED. Indeed, we detected that psychological ED represents 70% of all cases. Moreover, among organic causes, vascular etiology is recognized in 75.8% of cases, confirming its high prevalence when psychological forms are ruled out. In our cohort, 51% of patients with psychological ED showed normal penile erection after the first step of the procedure, allowing to obtain a quick and safe diagnosis, without continuing with further invasive procedures and time-consuming approaches. Then, 49% of patients with psychological ED did not respond to PGE-1 injection during the lower dose ICI test, but showed a normal penile erection once they left the hospital. Thus, only three patients required the complete ICI procedure to reach the diagnosis of psychological ED. Overall, these data show that when ICI test is first performed with the low PGE-1 dosage, 97.6% of psychological forms is detected, allowing saving time and costs (i.e., medication, tools, time/operator).

The reduction of spontaneous morning erections is one of the symptoms highly suggestive of hypogonadism, together with decreased nocturnal penile tumescence, decreased libido, and reduced testicular volume. Thus, the predictive role of some sexual function/dysfunction characteristics in the andrological diagnostic path has already been proposed. However, we demonstrated that this anamnestic parameter collected by unstructured interview is extremely useful also to recognize psychological ED. When predictive logistic models were applied in this study, the anamnestic evaluation remained the strong factor to suspect psychological ED. In particular, ED characteristics with a specific focus on the symptom characteristics in settings other than sexual intercourses, and the presence of spontaneous morning erections could guide the diagnostic ED workup. Even if several questionnaires have been validated so far to grade ED, they are not useful to discriminate among ED etiologies. Although psychological ED showed a lower IIEF-5 and IIEF-15 score compared to both vascular and hormonal forms, these variables did not enter in the predictive model. The main difference between structured and unstructured interviews lies in the possibility for the patient to self-fill in case of validated questionnaires without the need for clinician intervention. This aspect certainly represents an advantage in the andrological field, where the issues addressed are intimate and personal and the patient may experience some degree of embarrassment. For these reasons, obtaining ED characteristics by unstructured interviews requires a fully functioning trustworthy relationship between the clinician and the patient, because this relationship is known to guide decision-making and to influence the therapeutic success in many clinical settings. Here, we highlight how a strong clinician–patient relationship provides fundamental information that could help the clinician to unravel the ED diagnostic challenge. This aspect appears even more relevant when considering anthropometrical variables. Although psychological ED is more frequent in younger subjects, the age of the patients did not predict the ED etiology in any of the logistic regressions performed. Similarly, BMI did not enter in predictive models.

### Table 4 Multinomial logistic regression analysis performed to predict the response to ICI procedure

|             | B     | SE    | Wald  | p-Value | Exp(B)  | 95% CI Lower | 95% CI Upper |
|-------------|-------|-------|-------|---------|---------|--------------|--------------|
| Intercept   | 2.616 | 1.656 | 2.495 | 0.114   |         |              |              |
| Comorbidities number | -0.155 | 0.297 | 0.272 | 0.602   | 0.856   | 0.478        | 1.534        |
| Drug number | -0.079 | 0.100 | 0.623 | 0.430   | 0.924   | 0.760        | 1.124        |
| ED duration | 0.006  | 0.006 | 0.921 | 0.337   | 1.006   | 0.994        | 1.017        |
| IIEF-5      | -0.064 | 0.048 | 1.732 | 0.188   | 0.938   | 0.854        | 1.032        |
| ED at IIEF-15 | -0.037 | 0.035 | 1.164 | 0.281   | 0.963   | 0.900        | 1.031        |
| Smoke       | 0.633  | 0.470 | 1.819 | 0.177   | 1.884   | 0.750        | 4.730        |
| Ex-smoke    | -0.151 | 0.442 | 0.117 | 0.733   | 0.860   | 0.361        | 2.045        |
| Alcohol     | -0.365 | 0.417 | 0.770 | 0.380   | 0.694   | 0.307        | 1.570        |
| No hypertension | -0.859 | 0.516 | 2.779 | 0.096   | 0.423   | 0.154        | 1.163        |
| No diabetes mellitus | -0.224 | 0.515 | 0.189 | 0.664   | 0.800   | 0.292        | 2.193        |
| No dyslipidemia | -0.591 | 0.566 | 1.089 | 0.297   | 0.554   | 0.183        | 1.680        |
| No cardiovascular diseases | -1.013 | 0.630 | 2.581 | 0.108   | 0.363   | 0.106        | 1.250        |
| Impaired sexual desire | -0.509 | 0.447 | 1.293 | 0.255   | 0.601   | 0.250        | 1.445        |
| ED with masturbation | -0.099 | 0.473 | 0.044 | 0.835   | 0.906   | 0.359        | 2.289        |
| No morning erection | 1.288 | 0.525 | 6.019 | 0.014   | 3.626   | 1.296        | 10.148       |
| Gradual onset of ED | 0.400  | 0.458 | 0.763 | 0.382   | 1.493   | 0.608        | 3.666        |
| Constant ED | 0.641  | 0.458 | 1.960 | 0.162   | 1.898   | 0.774        | 4.654        |

Abbreviations: CI, confidence interval; ED, erectile dysfunction; ICI, intracavernosal injection; IIEF, International Index on Erectile Function; OR, odds ratio; SE, standard error.
**TABLE 5** Characteristics of the patients who are compared according to normal or abnormal penile response to ICI, considering the entire ICI procedure

| Feature                                      | ICI normal response (n = 123) | ICI reduced response (n = 56) | p-Value |
|----------------------------------------------|-------------------------------|-------------------------------|---------|
| Age (years)                                  | 54.3 ± 10.9                   | 58.8 ± 10.7                   | 0.011   |
| Body mass index (kg/m²)                      | 29.3 ± 5.1                    | 29.1 ± 5.3                    | 0.878   |
| Current smoker, n (%)                        | 37 (30.1)                     | 12 (22.1)                     | 0.153   |
| Ex-smoker, n (%)                             | 39 (31.7)                     | 22 (39.3)                     | 0.205   |
| Hypertension, n (%)                          | 51 (41.5)                     | 28 (50.0)                     | 0.183   |
| Diabetes mellitus, n (%)                     | 40 (32.5)                     | 18 (32.1)                     | 0.552   |
| Dyslipidemia, n (%)                          | 35 (28.5)                     | 20 (35.7)                     | 0.211   |
| Cardiovascular diseases, n (%)               | 17 (13.8)                     | 11 (19.6)                     | 0.218   |
| Comorbidities number                         | 1.5 ± 1.3                     | 1.7 ± 1.2                     | 0.604   |
| Chronic treated patients, n (%)              | 88 (71.5)                     | 43 (76.6)                     |         |
| Drugs number                                 | 2.5 ± 2.9                     | 3.0 ± 3.3                     | 0.256   |
| IIEF-5 score                                 | 11.5 ± 5.9                    | 8.5 ± 6.1                     | 0.003   |
| Erectile domain at IIEF-15                   | 11.8 ± 8.3                    | 8.4 ± 7.1                     | 0.008   |
| Erectile dysfunction at IIEF-15, n (%)        |                               |                               | <0.001  |
| Severe                                       | 61 (51.3)                     | 40 (72.7)*                    |         |
| Moderate                                     | 21 (17.6)                     | 5 (9.1)                       |         |
| Mild                                         | 30 (25.2)                     | 9 (16.4)                      |         |
| Absent                                       | 7 (5.9)                       | 1 (1.8)                       |         |
| ED duration (months)                         | 40.5 ± 42.4                   | 44.2 ± 3.62                   | 0.581   |
| ED duration > 2 years, n (%)                 | 53 (43.1)                     | 31 (55.4)                     | 0.086   |
| ED during masturbation, n (%)                | 32 (27.1)                     | 34 (61.8)                     | <0.001  |
| Impaired morning erections, n (%)            | 28 (22.8)                     | 30 (53.6)                     | <0.001  |
| Decreased sexual desire, n (%)               | 35 (28.5)                     | 11 (19.6)                     | 0.143   |
| Total testosterone (ng/ml)                   | 4.8 ± 1.5                     | 4.8 ± 1.9                     | 0.836   |
| LH (IU/L)                                    | 4.3 ± 2.3                     | 4.4 ± 1.9                     | 0.763   |
| FSH (IU/L)                                   | 6.2 ± 5.4                     | 6.2 ± 5.9                     | 0.996   |
| Estradiol (pg/ml)                            | 23.8 ± 8.5                    | 25.1 ± 10.1                   | 0.433   |
| Prostate-specific antigen (ng/ml)            | 1.3 ± 1.1                     | 1.3 ± 1.4                     | 0.750   |
| Prolactin (ng/ml)                            | 10.9 ± 5.0                    | 11.4 ± 5.4                    | 0.551   |
| TSH (µU/ml)                                  | 2.3 ± 4.7                     | 1.7 ± 1.0                     | 0.383   |

Note: Continuous variables are reported as mean ± standard deviation. Categorical variables are reported as number (percentage). p-Values are obtained by Mann–Whitney U-test.

Abbreviations: ED, erectile dysfunction; FSH, follicle-stimulating hormone; ICI, intracavernosal injection; IIEF, International Index on Erectile Function; LH, luteinizing hormone; TSH, thyroid-stimulating hormone.

confirming that we could not suspect the ED etiology on the basis of physical examination only. Moreover, patients’ medical history, number and type of both comorbidities and drugs chronically used did not enter the predictive mathematical model. We observed a lower cardiovascular disease rate in psychological ED, indirectly confirming the previously suggested link between vascular ED and cardiovascular disease.\(^{15}\)

In conclusion, according to our data, a negative history of cardiovascular disease, the presence of spontaneous morning erections, and ED absence during masturbation represent the crucial anamnestic points to be collected during the andrological evaluation to discriminate between psychological and vascular ED forms. Adding minimally specialized examinations to study the erection vascular component, the proposed two-step ICI procedure is performing very well at diagnosing psychological ED, reserving second-level tests for those patients who really need a deeper evaluation of the penile vascular status. These results should be carefully considered, as we detected a high psychological ED rate in our cohort, which could influence our
TABLE 6  Eco-color Doppler variables comparing patients with psychological ED to patients with other forms of ED

|                      | Psychological ED   | Not psychological ED | p-Value |
|----------------------|--------------------|----------------------|---------|
| **Systolic peak (cm/s)** |                    |                      |         |
| Right side           | 32.9 ± 9.1         | 23.0 ± 9.3           | 0.005   |
| Left side            | 39.8 ± 9.1         | 19.4 ± 8.7           | <0.001  |
| **End-diastolic peak (cm/s)** |                  |                      |         |
| Right side           | 3.2 ± 1.6          | 5.6 ± 2.2            | 0.003   |
| Left side            | 2.4 ± 2.5          | 5.2 ± 2.6            | 0.005   |

Note: Continuous variables are reported as mean ± standard deviation. p-Values are obtained by Mann–Whitney U-test.
Abbreviation: ED, erectile dysfunction.

conclusions. This incidence could be explained by our clinical practice, in which men with a likely vascular ED (i.e., diabetic ones) were not evaluated with ICI test.

ACKNOWLEDGMENTS

Authors are grateful to Elisa Magnani, Maria Laura Monzani, Andrea Craparo, Sara De Vincentis, Maria Chiara Decaroli, Michela Locaso, Antonino Russo, Daniela Domenici, Giulia Tartaro, Gisella Boselli, Gianluca Margiotta, Simone Pederzoli, Marta Caccian, Marilina Romeo, and Barbara Rossi who performed the first step of the ICI procedure at the Unit of Endocrinology, Department of Medical Specialties, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy.

Open Access Funding provided by Universita degli Studi di Modena e Reggio Emilia within the CRUI-CARE Agreement.

CONFLICT OF INTEREST

The authors have no conflicts of interest to disclose.

AUTHOR CONTRIBUTIONS

Daniele Santi conceived the study and analyzed the data. Daniele Santi, Giorgia Spaggiari, and Antonio R. M. Granata collected data. Daniele Santi and Giorgia Spaggiari interpreted results and drafted the article. Manuela Simoni and Antonio R. M. Granata revised the article critically for important intellectual content. All authors approved the final version of the manuscript.

REFERENCES

1. McCabe MP, Sharlip ID, Atalla E, et al. Definitions of sexual dysfunctions in women and men: a consensus statement from the Fourth International Consultation on Sexual Medicine 2015. J Sex Med. 2016;13(2):135-143.
2. Corona G, Lee DM, Forti G, et al. Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS). J Sex Med. 2010;7(4 Pt 1):1362-1380.
3. Domes T, Najafabadi BT, Roberts M, et al. Canadian Urological Association guideline: erectile dysfunction. Can Urol Assoc J. 2021;15(10):310-322.
4. Hazir B, Haberal HB, Asci A, Muneer A, Guldenoglu A. Erectile dysfunction management: a critical appraisal of clinical practice guidelines with the AGREE II instrument. Int J Impot Res. 2021. https://doi.org/10.1038/s41443-021-00442-7
5. Hackett G, Kirby M, Wylie K, et al. British Society for Sexual Medicine Guidelines on the management of erectile dysfunction in men-2017. J Sex Med. 2018;15(4):430-457.
6. Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633-641.
7. Ryu JK, Cho KS, Kim SJ, et al. Korean Society for Sexual Medicine and Andrology (KSSMA) guideline on erectile dysfunction. World J Mens Health. 2013;31(2):82-102.
8. Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012;87(8):766-778.
9. Salonia A, Bettocchi C, Boeri L, et al. European Association of Urology guidelines on sexual and reproductive health-2021 update: male sexual dysfunction. Eur Urol. 2021;80(3):333-357.
10. Mengesha Z, Perz J, Dune T, Ussher J. Preparedness of health care professionals for delivering sexual and reproductive health care to refugee and migrant women: a mixed methods study. Int J Environ Res Public Health. 2018;15(1):174.
11. Botfield JR, Newman CE, Lenette C, Albury K, Zwi AB. Using digital storytelling to promote the sexual health and well-being of migrant and refugee young people: a scoping review. Health Educ J. 2017;77(7):735-748.
12. Lue T. Erectile dysfunction. N Engl J Med. 2000;342(24):1802-1813.
13. Rinkūnienė E, Gimžauskaitė S, Badarienė J, Dženkevičiūtė V, Kovaitė M, Čypienė A. The prevalence of erectile dysfunction and its association with cardiovascular risk factors in patients after myocardial infarction. Medicina (Kaunas). 2021;57(10):1103.
14. Terentes-Printzios D, Ioakeimidis N, Rokkas K, Vlachopoulos C. Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs. Nat Rev Cardiol. 2022;19(1):59-74.
15. Yannas D, Frizza F, Vignozzi L, Corona G, Maggi M, Rastrelli G. Erectile dysfunction is a hallmark of cardiovascular disease: unavoidable matter of fact or opportunity to improve men’s health? J Clin Med. 2021;10(10):2221.
16. Corona G, Rastrelli G, Isidori A, et al. Erectile dysfunction and cardiovascular risk: a review of current findings. Expert Rev Cardiovasc Ther. 2020;18(3):155-164.
17. Montorsi P, Montorsi F, Schulman CC. Is erectile dysfunction the “tip of the iceberg” of a systemic vascular disorder? Eur Urol. 2003;44(3):352-354.
18. Sikka SC, Hellstrom WJG, Brock G, Morales AM. Standardization of vascular assessment of erectile dysfunction: standard operating procedures for duplex ultrasound. J Sex Med. 2013;10(1):120-129.
19. Lee B, Sikka SC, Randrup ER, et al. Standardization of penile blood flow parameters in normal men using intracavernous prostaglandin E1 and visual sexual stimulation. J Urol. 1993;149(1):49-52.
20. Melling B, Vaughan ED. Penile blood flow changes in the flaccid and erect state in potent young men measured by duplex scanning. J Urol. 1990;144(4):894-896.
21. Speel TGM, Van L H, Wijkstra H, Meuleman EJH. Penile duplex pharmaco-ultrasonography revisited: revalidation of the parameters of the cavernous arterial response. J Urol. 2003;169(1):216-220.
22. Brock G, Breza Jan, Lue TF, Tanagho EA. High flow priapism: a spectrum of disease. J Urol. 1993;150(3):968-971.
23. Dewitte M, Bettocchi C, Carvalho J, et al. A psychosocial approach to erectile dysfunction: position statements from the European Society of Sexual Medicine (ESSM). Sex Med. 2021;9(6):100434.
24. Zou Z, Lin H, Zhang Y, Wang R. The role of nocturnal penile tumescence and rigidity (nptr) monitoring in the diagnosis of psychogenic erectile dysfunction: a review. Sex Med Rev. 2019;7(3):442-454.
25. Mccab M, Althof SE. A systematic review of the psychosocial outcomes associated with erectile dysfunction: does the impact of erectile dysfunction extend beyond a man’s inability to have sex? J Sex Med. 2014;11(2):347-363.
26. Corona G, Petrone L, Mannucci E, et al. Assessment of the relational factor in male patients consulting for sexual dysfunction: the concept of couple sexual dysfunction. J Androl. 2006;27(6):795-801.
27. Rosen R, Cappelleri J, Smith M, Lipsky J, Peña B. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11(6):319-326.
28. Belew D, Klaassen Z, Lewis RW. Intracavernosal injection for the diagnosis, evaluation, and treatment of erectile dysfunction: a review. Sex Med Rev. 2015;3(1):11-23.
29. Rastrelli G, Cipriani S, Craparo A, et al. The physician’s gender influences the results of the diagnostic workup for erectile dysfunction. Andrology. 2020;8(3):671-679.
30. Goldstein I, Auerbach S, Padma-Nathan H, Rajfer J, Fitch W, Schmitt L. Axial penile rigidity as primary efficacy outcome during multi-institutional in-office dose titration clinical trials with alprostadil alfadex in patients with erectile dysfunction. Alprostadil Alfadex Study Group. Int J Impot Res. 2000;12(4):205-211.
31. Beglinger L, Gaydos B, Tangphaodaniels O, et al. Practice effects and the use of alternate forms in serial neuropsychological testing. Arch Clin Neuropsychol. 2005;20(4):517-529.
32. Ivnik RJ, Smith GE, Lucas JA, et al. Testing normal older people three or four times at 1- to 2-year intervals: defining normal variance. Neuropsychology. 1999;13(1):121-127.
33. Donatucci Craig, Lue TF. The combined intracavernous injection and stimulation test: diagnostic accuracy. J Urol. 1992;148(1):61-62.
34. Hatzichristou DG, De Tejada IS, Kupferman S, et al. In vivo assessment of trabecular smooth muscle tone, its application in pharmacocavernosometry and analysis of intracavernous pressure determinants. J Urol. 1995;153(4):1126-1135.
35. Vaughan ED. Atlas of Clinical Urology. Springer; 1999.
36. Sizar O, Schwartz J. Hypogonadism. StatPearls Publishing LLC; 2021.
37. Santi D, Corona G. Primary and secondary hypogonadism. In: Simoni M, Huhtaniemi I, eds. Endocrinology of the Testis and Male Reproduction. Springer; 2017.
38. Gool S, Lipkin M. The doctor-patient relationship: challenges, opportunities, and strategies. J Gen Intern Med. 1999;14(Suppl 1):S26-S33.
39. Ha JF, Longnecker N. Doctor-patient communication: a review. Ochsner J. 2010;10(1):38-43.
40. Hoff T, Collinson GE. How do we talk about the physician-patient relationship? What the nonempirical literature tells us. Med Care Res Rev. 2017;74(3):251-285.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Santi D, Spaggiari G, Simoni M, Granata ARM. Accurate and time-saving, two-step intracavernosal injection procedure to diagnose psychological erectile dysfunction. Andrology. 2022;10:852-862. https://doi.org/10.1111/andr.13175